CVS Health kicked off the third-largest corporate bond sale on record to fund its acquisition of Aetna, testing the appetite of a market that’s off to its worst annual start in decades.
The pharmacy giant plans to issue US$40 billion of the investment-grade debt in a nine-part offering, people with knowledge of the matter said. That would be surpassed only by Verizon Communication’s US$49 billion offering in 2013 and Anheuser-Busch InBev’s US$46 billion sale two years ago.
Order books of more than US$120 billion for the nine-tranche trade—the third largest US dollar high-grade corporate deal on record, according to IFR data—brought some relief after new issues have traded wider in secondary markets of late.
“This is the deal of 2018,” Matt Brill, senior portfolio manager at Invesco, told IFR. “The market needs this to do well.”
The CVS bond, which will help finance the US$69 billion acquisition of health insurer Aetna, has been hailed as a crucial test for the market that has provided some of the largest corporations with cheap financing for several consecutive years.
CVS has been eyeing other currencies as well due to the large amount of debt it needed to raise. But hefty demand for the US dollar offering helped alleviate concerns about investor demand that has tapered off in recent weeks, according to Lipper data.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI